Get the Stockscreener App
0.77
1.53%
-0.00845
Iridex Corp stock is traded at $0.77, with a volume of 59,207.
It is down -1.53% in the last 24 hours and down -18.05% over the past month.
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
See More
Previous Close:
$0.7616
Open:
$0.75
24h Volume:
59,207
Relative Volume:
0.89
Market Cap:
$13.40M
Revenue:
$52.58M
Net Income/Loss:
$-3.28M
P/E Ratio:
-3.9958
EPS:
-0.1927
Net Cash Flow:
$-2.53M
1W Performance:
-12.39%
1M Performance:
-18.05%
6M Performance:
-46.05%
1Y Performance:
-38.02%
1-Day Range:
$0.7406
$0.77
1-Week Range:
$0.7001
$0.9765
52-Week Range:
$0.7001
$1.6481
Iridex Corp Stock (IRIX) Company Profile
Name
Iridex Corp
Sector
Industry
Phone
(650) 940-4700
Address
1212 TERRA BELLA AVE, MOUNTAIN VIEW, CA
Compare IRIX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRIX
Iridex Corp
|
0.77 | 13.63M | 52.58M | -3.28M | -2.53M | -0.1927 |
ABT
Abbott Laboratories
|
116.12 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
330.26 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
93.14 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
50.73 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.89 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Iridex Corp Stock (IRIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-17 | Resumed | ROTH Capital | Buy |
| Dec-21-16 | Initiated | ROTH Capital | Buy |
| Jan-26-16 | Initiated | Singular Research | Buy |
| Jan-03-07 | Initiated | First Albany | Buy |
Iridex Corp Stock (IRIX) Latest News
IRIDEX Corp (IRIX) (Q2 2026) Earnings Call Highlights: Cyclo-G6 - GuruFocus
IRIX Looks 45.3% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Earnings call transcript: IRIDEX misses Q2 2026 estimates as cash flow turns positive - Investing.com South Africa
IRIDEX Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
Is IRIDEX Corp (IRIX) Positioned for Growth After Q2 Earnings Mi - GuruFocus
IRIDEX Q2 Revenue Falls 7% as Retina Weakness Offsets Glaucoma Growth - Minichart
Form 8K IRIDEX Corporation For: 18 August By Investing.com - Investing.com Canada
Full Transcript: Iridex Q2 2026 Earnings Call - Benzinga
IRIDEX Corp reports results for the quarter ended June 30Earnings Summary - TradingView
IRIDEX CORP Q2 2026: Revenue $12.6M, EPS $(0.07) — 10-Q Summary - TradingView
IRIDEX (IRIX) glaucoma sales rise as retina revenue falls - Stock Titan
IRIDEX earnings missed by $0.05, revenue fell short of estimates - Investing.com
Iridex Reports Q2 2026 Revenue $12.6M, Net Loss $1.3M; Cyclo G6 Probe Growth Boosts Glaucoma Sales - TradingView
Iridex falls short on Q2 revenue and earnings expectations - Investing.com
Iridex falls short on Q2 revenue and earnings expectations By Investing.com - Investing.com Australia
IRIDEX ($IRIX) Releases Q2 2026 Earnings - Quiver Quantitative
Iridex Latest Results: FY26 sales guidance affirmed at $51M-$53M, below est - scanx.trade
Iridex Q2 revenue misses estimate as loss widens to $0.07 - scanx.trade
Iridex: Q2 Earnings Snapshot - marketscreener.com
Iridex Reports Second Quarter 2026 Financial Results - GlobeNewswire
Iridex (NASDAQ:IRIX): Why Is Ophthalmic Systems And Procedure Activity in Focus Today? - Kalkine Media
IRIDEX Corp (IRIX) (Q2 2026) Earnings Call Highlights: Cyclo-G6 Surges 35% as Company Achieves ... By GuruFocus - Investing.com Canada
IRIX|IRIDEX Corp|Price:0.880|Chg%:+0.024 - TradingKey
IRIDEX Corp (IRIX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IRIDEX Corp (IRIX) Stock News Today - TradingKey
Iridex schedules Q2 business update after Aug. 18 close - Stock Titan
Iridex to Report Second Quarter 2026 Financial Results on August 18, 2026 - Yahoo Finance
IRIX Faces Continued Pressure Near Key Support Levels – IRIDEX Corporation (IRIX) at $0.86Wyckoff Distribution - dars.gov.et
IRIDEX Corp (IRIX) Institutional Confidence - TradingKey
IRIX|IRIDEX Corp|Price:0.889|Chg%:-0.002 - TradingKey
IRIDEX Corp (IRIX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
IRIDEX Corp (IRIX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IRIDEX Corp (IRIX) Cash Flow - TradingKey
IRIDEX Corp (IRIX) Valuation: PE, PB & Fair Value Analysis - TradingKey
IRIX|IRIDEX Corp|Price:0.783|Chg%:-0.147 - TradingKey
IRIDEX Corp (IRIX) Income Statement - TradingKey
IRIDEX Corp (IRIX) Earnings Date & Reports & Earnings News - TradingKey
IRIDEX Corp (IRIX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
IRIDEX Corp (IRIX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IRIDEX Corp (IRIX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IRIX|IRIDEX Corp|Price:0.930|Chg%:+0.050 - TradingKey
Iridex expands EyeProGPO offering with EndoProbe handpieces - Investing.com
More Than 4,300 EyeProGPO Members Gain Preferred EndoProbe Pricing - Stock Titan
Iridex Expands EyeProGPO Offering to Include EndoProbe Handpieces - Quiver Quantitative
Iridex Board Warns of Legal Risks in Stealth Proxy Campaign by Major Shareholder Novel Inspiration - Minichart
Form 4 IRIDEX Corporation For: 14 July By Investing.com - Investing.com Nigeria
IRIDEX CORP (IRIX) grants CFO 30K RSUs and 170K options - Stock Titan
Form 13D/A IRIDEX CORP For: 13 July By Investing.com - Investing.com Nigeria
Iridex Corp (Nasdaq: IRIX) investor group reports 29.92% ownership stake - Stock Titan
Form 4 IRIDEX Corporation For: 8 July By Investing.com - Investing.com Nigeria
Novel Inspiration gains IRIDEX (IRIX) shares as quarterly note interest - Stock Titan
Iridex Corp Stock (IRIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Iridex Corp Stock (IRIX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dizon Romeo R | Chief Financial Officer |
Jun 11 '26 |
Buy |
1.14 |
1,675 |
1,909 |
135,000 |
| Dizon Romeo R | Chief Financial Officer |
Jun 08 '26 |
Buy |
1.12 |
2,400 |
2,688 |
133,325 |
| Dizon Romeo R | Chief Financial Officer |
Jun 05 '26 |
Buy |
1.15 |
2,521 |
2,899 |
130,925 |
| Dizon Romeo R | Chief Financial Officer |
Jun 03 '26 |
Buy |
1.17 |
2,400 |
2,808 |
128,404 |
| Dizon Romeo R | Chief Financial Officer |
May 26 '26 |
Buy |
1.00 |
5,004 |
5,004 |
126,004 |
| Dizon Romeo R | Chief Financial Officer |
Mar 06 '26 |
Buy |
1.26 |
1,110 |
1,399 |
121,000 |
| Dizon Romeo R | Chief Financial Officer |
Feb 17 '26 |
Buy |
1.34 |
2,200 |
2,942 |
119,890 |
| Dizon Romeo R | Chief Financial Officer |
Feb 12 '26 |
Buy |
1.43 |
1,500 |
2,145 |
117,690 |
| Dizon Romeo R | Chief Financial Officer |
Feb 10 '26 |
Buy |
1.46 |
1,000 |
1,460 |
116,190 |
| Dizon Romeo R | Chief Financial Officer |
Feb 03 '26 |
Buy |
1.38 |
2,500 |
3,450 |
115,190 |
1.33%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):